benzyloxycarbonylvalyl-alanyl-aspartyl-fluoromethyl-ketone has been researched along with Multiple-System-Atrophy* in 1 studies
1 other study(ies) available for benzyloxycarbonylvalyl-alanyl-aspartyl-fluoromethyl-ketone and Multiple-System-Atrophy
Article | Year |
---|---|
Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple system atrophy).
In the present study we assessed the neuroprotective effects of the pan-caspase inhibitor z-VAD.fmk [N-benzyloxycarbony-valine-alanine-aspartate-(OMe)-fluoromethylketone], and the caspase-3 inhibitor Ac-DEVD.CHO (acetyl-aspartate-chloromethylketone) in the double-lesion rat model of striatonigral degeneration (SND), the core pathology underlying levodopa-unresponsive parkinsonism associated with multiple system atrophy (MSA). Male Wistar rats were divided into three groups, receiving either Ac-DEVD.CHO, z-VAD.fmk or normal saline before lesion surgery, comprising a sequential unilateral quinolinic acid (QA) lesion of the striatum followed by a 6-hydroxydopamine (6-OHDA) lesion of the ipsilateral medial forebrain bundle. At 2 weeks post lesion, all rats underwent testing of spontaneous nocturnal locomotor behavior in an automated Photobeam Activity System (FlexField). Immunohistochemistry was performed with tyrosine hydroxylase, dopamine and cyclic adenosine 3',5'-monophosphate-regulated phosphoprotein and glial fibrillary acidic protein antibodies. Morphometry was performed using computerized image analysis. Behavioral and morphological analysis failed to show striatal or nigral protection in caspase inhibitor-treated animals. Our findings suggest that anti-apoptotic strategies are unrewarding in the SND rat model and, therefore, alternative neuroprotective interventions such as anti-glutamatergic agents or inhibitors of microglial activation should be explored instead. Topics: Amino Acid Chloromethyl Ketones; Analysis of Variance; Animals; Basal Ganglia; Behavior, Animal; Caspase Inhibitors; Cell Count; Cell Size; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Functional Laterality; Immunohistochemistry; Male; Motor Activity; Multiple System Atrophy; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Oligopeptides; Oxidopamine; Phosphoproteins; Quinolinic Acid; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2005 |